Quality assessment of randomized controlled trial abstracts on drug therapy of periodontal disease from the abstracts published in dental Science Citation Indexed journals in the last ten years

Randomized controlled trials (RCTs) provide the highest level of evidence and are likely to influence clinical decision-making. This study evaluated the reporting quality of RCT abstracts on drug therapy of periodontal disease and assessed the associated factors. The Pubmed database was searched for periodontal RCTs published in Science Citation Indexed (SCI) dental journals from 2010/01/01 to 2019/07/17. Information was extracted from the abstracts according to a modified Consolidated Standards of Reporting Trials (CONSORT) guideline checklist. The data was analyzed using descriptive statistical analysis and the statistical associations were examined using the linear regression analysis (P <0.05). This study retrieved 1715 articles and 249 of them were finally included. The average overall CONSORT score was 15.6 ± 3.4, which represented 40.9% (±0.6) of CONSORT criteria filling. The reporting rate of some items (trial design, numbers analyzed, confidence intervals, intention-to-treat analysis or per-protocol analysis, harms, registration) was less than 30%. The adequate reporting rate of some items (participants, randomization, numbers analyzed, confidence intervals, intention-to-treat analysis or per protocol analysis) was no more than 4%. None of the abstracts reported funding. According to the multivariable linear regression results, number of authors (P=0.030), word count (P <0.001), continent (P=0.003), structured format (P <0.001), type of periodontal disease (P <0.001) and international collaboration (P=0.023) have a significant association with reporting quality. The quality of RCT abstracts on drug therapy of periodontal disease in SCI dental journals remained suboptimal. More efforts should be made to improve RCT abstracts reporting quality

Predictors of lung adenocarcinoma with leptomeningeal metastases: A 2022 targeted-therapy-assisted molGPA model

Objective: To explore prognostic indicators of lung adenocarcinoma with leptomeningeal metastases (LM) and provide an updated graded prognostic assessment model integrated with molecular alterations (molGPA). Methods: A cohort of 162 patients was enrolled from 202 patients with lung adenocarcinoma and LM. By randomly splitting data into the training (80%) and validation (20%) sets, the Cox regression and random survival forest methods were used on the training set to identify statistically significant variables and construct a prognostic model. The C-index of the model was calculated and compared with that of previous molGPA models. Results: The Cox regression and random forest models both identified four variables, which included KPS, LANO neurological assessment, TKI therapy line, and controlled primary tumor, as statistically significant predictors. A novel targeted-therapy-assisted molGPA model (2022) using the above four prognostic factors was developed to predict LM of lung adenocarcinoma. The C-indices of this prognostic model in the training and validation sets were higher than those of the lung-molGPA (2017) and molGPA (2019) models. Conclusions: The 2022 molGPA model, a substantial update of previous molGPA models with better prediction performance, may be useful in clinical decision making and stratification of future clinical trials

Single-cell RNA sequencing reveals cell type-specific immune regulation associated with human neuromyelitis optica spectrum disorder

IntroductionOne rare type of autoimmune disease is called neuromyelitis optica spectrum disorder (NMOSD) and the peripheral immune characteristics of NMOSD remain unclear.MethodsHere, single-cell RNA sequencing (scRNA-seq) is used to characterize peripheral blood mononuclear cells from individuals with NMOSD.ResultsThe differentiation and activation of lymphocytes, expansion of myeloid cells, and an excessive inflammatory response in innate immunity are observed. Flow cytometry analyses confirm a significant increase in the percentage of plasma cells among B cells in NMOSD. NMOSD patients exhibit an elevated percentage of CD8+ T cells within the T cell population. Oligoclonal expansions of B cell receptors are observed after therapy. Additionally, individuals with NMOSD exhibit elevated expression of CXCL8, IL7, IL18, TNFSF13, IFNG, and NLRP3.DiscussionPeripheral immune response high-dimensional single-cell profiling identifies immune cell subsets specific to a certain disease and identifies possible new targets for NMOSD

Organosilicon Based Electrolytes for Lithium-Ion Batteries

Organosilicon compounds have attracted considerable interest as electrolytes for lithium-ion batteries because they are nontoxic, nonflammable, as well as have lower glass transition temperatures, lower vapor pressure and higher flash point than commerical alkyl carbonates. These compounds can improve the electrochemical performances and safety of lithium-ion batteries when used as electrolyte solvents or additives in the electrolytes. In this paper, the recent advances of organosilicon compounds both as electrolyte solvents and additives are reviewed. Organosilicon electrolytes containing ethylene oxide (EO) substituents with or without carbon spacer between silicon atom and EO unit are specially remarked as safe electrolytes. Organosilicon compounds as functional additives are also introduced in terms of the capabilities of passive film formation, flame-retardant, and acid/water scavenger

MET Amplification as a Resistance Driver to TKI Therapies in Lung Cancer: Clinical Challenges and Opportunities

Targeted therapy has emerged as an important pillar for the standard of care in oncogene-driven non-small cell lung cancer (NSCLC), which significantly improved outcomes of patients whose tumors harbor oncogenic driver mutations. However, tumors eventually develop resistance to targeted drugs, and mechanisms of resistance can be diverse. MET amplification has been proven to be a driver of resistance to tyrosine kinase inhibitor (TKI)-treated advanced NSCLC with its activation of EGFR, ALK, RET, and ROS-1 alterations. The combined therapy of MET-TKIs and EGFR-TKIs has shown outstanding clinical efficacy in EGFR-mutated NSCLC with secondary MET amplification-mediated resistance in a series of clinical trials. In this review, we aimed to clarify the underlying mechanisms of MET amplification-mediated resistance to tyrosine kinase inhibitors, discuss the ways and challenges in the detection and diagnosis of MET amplifications in patients with metastatic NSCLC, and summarize the recently published clinical data as well as ongoing trials of new combination strategies to overcome MET amplification-mediated TKI resistance

MET Amplification as a Resistance Driver to TKI Therapies in Lung Cancer: Clinical Challenges and Opportunities

Targeted therapy has emerged as an important pillar for the standard of care in oncogene-driven non-small cell lung cancer (NSCLC), which significantly improved outcomes of patients whose tumors harbor oncogenic driver mutations. However, tumors eventually develop resistance to targeted drugs, and mechanisms of resistance can be diverse. MET amplification has been proven to be a driver of resistance to tyrosine kinase inhibitor (TKI)-treated advanced NSCLC with its activation of EGFR, ALK, RET, and ROS-1 alterations. The combined therapy of MET-TKIs and EGFR-TKIs has shown outstanding clinical efficacy in EGFR-mutated NSCLC with secondary MET amplification-mediated resistance in a series of clinical trials. In this review, we aimed to clarify the underlying mechanisms of MET amplification-mediated resistance to tyrosine kinase inhibitors, discuss the ways and challenges in the detection and diagnosis of MET amplifications in patients with metastatic NSCLC, and summarize the recently published clinical data as well as ongoing trials of new combination strategies to overcome MET amplification-mediated TKI resistance

Synergistic film-forming effect of oligo(ethylene oxide)-functionalized trimethoxysilane and propylene carbonate electrolytes on graphite anode

Oligo(ethylene oxide)-functionalized trialkoxysilanes can be used as novel electrolytes for high-voltage cathode, such as LiCoO2 (4.35 V) and Li1.2Ni0.2Mn0.6O2 (4.6 V); however, they are not well compatible with graphite anode. In this study, a synergistic solid electrolyte interphase (SEI) film-forming effect between [3-[2-(2-methoxyethoxy)ethoxy]propyl]-trimethoxysilane (TMSM2) and propylene carbonate (PC) on graphite electrode was investigated. Excellent SEI film-forming capability and cycling performance was observed in graphite/Li cells using the electrolyte of 1 M LiPF6 in the binary solvent of TMSM2 and PC, with the PC content in the range of 10-30 vol.%. Meanwhile, the graphite/Li cells delivered higher specific capacity and better capacity retention in the electrolyte of 1 M LiPF6 in TMSM2 and PC (TMSM2:PC = 9:1, by vol.), compared with those in the electrolyte of 1 M LiPF6 in TMSM2 and EC (TMSM2:EC = 9:1, by vol.). The synergistic SEI film-forming properties of TMSM2 and PC on the surface of graphite anode was characterized by electrolyte solution structure analysis through Raman spectroscopy and surface analysis detected by scanning electron microscopy (SEM), energy dispersive spectroscopy (EDS), and Fourier transform infrared spectroscopy (FT-IR) analysis

triethoxysilanewitholigoethyleneoxidesubstituentasfilmformingadditiveforgraphiteanode

{3-2-(2-methoxyethoxy) ethoxy-propyl} triethoxysilane (TESM2) was synthesized and used as an electrolyte additive to improve the performances of lithium-ion batteries (LIBs). The electrochemical properties of the electrolyte (1 mol/L lithium hexafluorophosphate (LiPF _6)/ethylene carbonate (EC):diethylene carbonate (DEC):dimethyl carbonate (DMC), 1:1:1) with different contents of TESM2 were characterized by ionic conductivity measurement, galvanostatic charge/discharge test of graphite/Li half cells, and electrochemical impedance spectroscopy. Both the cycling performances and C-rate capabilities of graphite/Li half cells were significantly improved with an optimized content of 15% TESM2 in the electrolyte. The graphite/Li half cell delivered a very high specific capacity of 370 mAh/g at 0.2C rate without any capacity loss for 60 cycles, and retained a capacity of 292 mAh/g at 2C rate. The solid electrolyte interphase (SEI) film on the surface of the graphite anode was investigated by scanning electron microscopy (SEM) and energy dispersive spectroscopy (EDS), indicating that TESM2 was effectively involved in the formation of SEI film on the surface of graphite

Expression profile of plasma microRNAs and their roles in diagnosis of mild to severe traumatic brain injury.

Traumatic brain injury (TBI) is associated with trauma-related death. In this study, we evaluated differences in the expression of plasma microRNAs (miRNAs) in patients with different degrees of TBI, and explored the potential of miRNAs for use as diagnostic TBI biomarkers. The miRNA microarray results showed upregulation of 65, 33, and 16 miRNAs and downregulation of 29, 27, and 6 miRNAs in patients with mild, moderate, and severe TBI, respectively, compared with healthy controls. Thirteen miRNAs (seven upregulated and six downregulated) were found to be present in all TBI groups. Seven upregulated miRNAs were selected for validation in an enlarged cohort of samples and showed good diagnostic accuracy. The expression levels of miR-3195 and miR-328-5p were higher in the severe TBI group than in the mild and moderate TBI groups. In summary, our study demonstrates different expression profiles in plasma miRNAs among patients with mild to severe TBI. A subset of seven miRNAs can be used for diagnosis of TBI. Moreover, miR-3195 and miR-328-5p may be utilized during diagnosis to distinguish mild and moderate TBI from severe TBI